4.4 Article

Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation

期刊

DERMATOLOGY
卷 231, 期 2, 页码 184-190

出版社

KARGER
DOI: 10.1159/000431175

关键词

Acne inversa; Classification; Clinical signs; Diagnostic criteria; Hidradenitis suppurativa; Severity assessment

资金

  1. AbbVie
  2. Astra-Zeneca
  3. Biogen-Idec
  4. Bristol Meyers Squibb
  5. Immundiagnostik AG
  6. Intendis
  7. LVMH
  8. Merz
  9. Novartis
  10. Pierre Fabre
  11. UCB
  12. Almirall
  13. Amgen
  14. BASF
  15. Celgene
  16. Centocor
  17. Eli Lilly
  18. Foamix
  19. Forward Pharma
  20. Galderma
  21. Janssen
  22. Leo Pharma
  23. Medac
  24. MSD
  25. Miltenyi Biotech
  26. Pfizer
  27. Teva
  28. VBL
  29. Xenoport
  30. Actelion
  31. Janssen-Cilag

向作者/读者索取更多资源

Background: Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating disease, which inflicts a significant burden on patients and is associated with comorbid disorders, such as significantly reduced quality of life, depression, stigmatization, inactivity, working disability, impairment of sexual health and several cardiovascular risk factors. Aims/Methods: To implement an expert consensus on the diagnostic criteria, severity and classification assessment, and an assessment of anti-inflammatory treatment effectiveness based on current evidence. Results: This article provides criteria for diagnosis, severity assessment, classification and evaluation of HS patients. Conclusion: The provided criteria can be used as tools for the promotion of uniformity in HS evaluation and facilitation of early and timely identification and referral in the primary care setting and thorough and efficient evaluation in daily clinical practice. (C) 2015 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据